IMGN
Income statement / Annual
Last year (2022), ImmunoGen, Inc.'s total revenue was $108.78 M,
a decrease of 0.00% from the previous year.
In 2022, ImmunoGen, Inc.'s net income was -$222.93 M.
See ImmunoGen, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
06/30/2016 |
06/30/2015 |
06/30/2014 |
| Operating Revenue |
$108.78 M
|
$108.78 M
|
$132.30 M
|
$82.27 M
|
$53.82 M
|
$115.45 M
|
$48.63 M
|
$60.00 M
|
$85.54 M
|
$59.90 M
|
| Cost of Revenue |
$176,000.00 |
$176,000.00 |
$114.59 M |
$114.52 M |
$173.89 M |
$139.74 M |
$141.31 M |
$146.92 M |
$111.77 M |
$106.96 M |
| Gross Profit |
$108.61 M |
$108.61 M |
$17.71 M |
-$32.25 M |
-$120.07 M |
-$24.29 M |
-$92.68 M |
-$86.91 M |
-$26.23 M |
-$47.06 M |
| Gross Profit Ratio |
1 |
1 |
0.13 |
-0.39 |
-2.23 |
-0.21 |
-1.91 |
-1.45 |
-0.31 |
-0.79 |
| Research and Development
Expenses |
$213.37 M
|
$213.37 M
|
$114.59 M
|
$114.52 M
|
$173.89 M
|
$139.74 M
|
$141.31 M
|
$146.92 M
|
$111.77 M
|
$106.96 M
|
| General & Administrative
Expenses |
$0.00
|
$43.81 M
|
$38.60 M
|
$38.49 M
|
$36.72 M
|
$33.91 M
|
$38.53 M
|
$36.92 M
|
$28.23 M
|
$24.47 M
|
| Selling & Marketing
Expenses |
$0.00
|
$72.32 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$116.13 M
|
$116.13 M
|
$38.60 M
|
$38.49 M
|
$36.72 M
|
$33.91 M
|
$38.53 M
|
$36.92 M
|
$28.23 M
|
$24.47 M
|
| Other Expenses |
$3.35 M |
$3.35 M |
$1.21 M |
$5.01 M |
$3.33 M |
$2.61 M |
$0.00 |
$304,000.00 |
-$848,000.00 |
$167,000.00 |
| Operating Expenses |
$329.50 M |
$329.50 M |
$153.19 M |
$153.01 M |
$210.60 M |
$173.65 M |
$43.54 M |
$183.83 M |
$140.00 M |
$131.43 M |
| Cost And Expenses |
$329.68 M |
$329.68 M |
$153.19 M |
$153.01 M |
$210.60 M |
$173.65 M |
$184.85 M |
$183.83 M |
$140.00 M |
$131.43 M |
| Interest Income |
$4.34 M |
$51,000.00 |
$729,000.00 |
$4.42 M |
$0.00 |
$0.00 |
$20.51 M |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$4.17 M |
$4.17 M |
$23.20 M |
$16.97 M |
$10.73 M |
$16.72 M |
$0.00 |
$20.13 M |
$5.44 M |
$0.00 |
| Depreciation &
Amortization |
$3.35 M
|
-$1.08 M
|
$115.80 M
|
$26.45 M
|
$7.41 M
|
$5.96 M
|
$6.01 M
|
$5.33 M
|
$5.51 M
|
$4.60 M
|
| EBITDA |
-$217.55 M
|
-$217.55 M
|
-$19.68 M
|
-$65.73 M
|
-$153.45 M
|
-$55.60 M
|
-$125.20 M
|
-$123.53 M
|
-$55.30 M
|
-$71.53 M
|
| EBITDA Ratio |
-2 |
-2 |
-0.15 |
-0.8 |
-2.85 |
-0.48 |
-2.57 |
-2.06 |
-0.65 |
-1.19 |
| Operating Income Ratio
|
-2.03
|
-2.03
|
-1.02
|
-1.12
|
-2.98
|
-0.51
|
-2.7
|
-2.06
|
-0.64
|
-1.19
|
| Total Other
Income/Expenses Net |
-$818,000.00
|
-$14.23 M
|
-$21.99 M
|
-$11.96 M
|
-$8.36 M
|
-$37.03 M
|
-$25.52 M
|
-$19.83 M
|
-$6.28 M
|
$167,000.00
|
| Income Before Tax |
-$221.71 M |
-$221.71 M |
-$44.37 M |
-$104.13 M |
-$167.87 M |
-$96.01 M |
-$156.73 M |
-$143.66 M |
-$60.74 M |
-$71.36 M |
| Income Before Tax Ratio
|
-2.04
|
-2.04
|
-0.34
|
-1.27
|
-3.12
|
-0.83
|
-3.22
|
-2.39
|
-0.71
|
-1.19
|
| Income Tax Expense |
$1.22 M |
$1.22 M |
$22.31 M |
$17.96 M |
$7.39 M |
$37.03 M |
$0.00 |
$19.83 M |
$6.28 M |
-$167,000.00 |
| Net Income |
-$222.93 M |
-$222.93 M |
-$66.68 M |
-$122.09 M |
-$167.87 M |
-$96.01 M |
-$156.73 M |
-$143.66 M |
-$60.74 M |
-$71.36 M |
| Net Income Ratio |
-2.05 |
-2.05 |
-0.5 |
-1.48 |
-3.12 |
-0.83 |
-3.22 |
-2.39 |
-0.71 |
-1.19 |
| EPS |
-0.88 |
-0.88 |
-0.38 |
-0.82 |
-1.2 |
-0.98 |
-1.8 |
-1.65 |
-0.71 |
-0.83 |
| EPS Diluted |
-0.88 |
-0.88 |
-0.38 |
-0.82 |
-1.2 |
-0.98 |
-1.8 |
-1.65 |
-0.71 |
-0.83 |
| Weighted Average Shares
Out |
$253.33 M
|
$253.63 M
|
$176.15 M
|
$148.31 M
|
$139.95 M
|
$98.07 M
|
$87.08 M
|
$86.98 M
|
$86.04 M
|
$85.48 M
|
| Weighted Average Shares
Out Diluted |
$253.63 M
|
$253.63 M
|
$176.15 M
|
$148.31 M
|
$139.95 M
|
$98.07 M
|
$87.08 M
|
$86.98 M
|
$86.04 M
|
$85.48 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
